Needham & Company LLC Forecasts Strong Price Appreciation for Liquidia Technologies (NASDAQ:LQDA) Stock

Key Points

• Needham & Company LLC has raised its price target for Liquidia Technologies from $32.00 to $36.00, indicating a potential upside of 49.38% from the stock's current price and maintaining a "buy" rating.
• Liquidia Technologies reported earnings of ($0.49) per share, missing the consensus estimate while achieving a revenue of $8.84 million, significantly above analyst expectations.
• Despite mixed analyst ratings, with one "sell," one "hold," and six "buy" ratings, Liquidia Technologies has a current market capitalization of $2.06 billion and a moderate buy average rating.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) had its price objective hoisted by Needham & Company LLC from $32.00 to $36.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Needham & Company LLC's price objective would indicate a potential upside of 49.38% from the company's current price.

A number of other analysts have also issued reports on the company. Oppenheimer set a $13.00 price target on Liquidia Technologies and gave the stock an "underperform" rating in a research note on Monday, May 19th. HC Wainwright raised their target price on Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, May 28th. Raymond James Financial lifted their price objective on Liquidia Technologies from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a report on Friday, May 9th. Wells Fargo & Company lifted their target price on Liquidia Technologies from $23.00 to $25.00 and gave the stock an "overweight" rating in a research report on Thursday, June 12th. Finally, Bank of America decreased their target price on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a research report on Wednesday, June 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $28.78.

Liquidia Technologies Stock Up 13.7%

Liquidia Technologies stock opened at $24.10 on Tuesday. The company has a debt-to-equity ratio of 2.08, a quick ratio of 2.91 and a current ratio of 2.93. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -15.25 and a beta of 0.14. Liquidia Technologies has a fifty-two week low of $8.26 and a fifty-two week high of $24.83. The stock's fifty day moving average is $15.83 and its two-hundred day moving average is $15.29.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). The firm had revenue of $8.84 million during the quarter, compared to analyst estimates of $3.90 million. Liquidia Technologies had a negative net margin of 903.80% and a negative return on equity of 177.91%. Liquidia Technologies's revenue for the quarter was up 141.5% compared to the same quarter last year. Analysts predict that Liquidia Technologies will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia Technologies

In other Liquidia Technologies news, CFO Michael Kaseta sold 30,000 shares of the business's stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $20.00, for a total value of $600,000.00. Following the transaction, the chief financial officer owned 376,412 shares in the company, valued at $7,528,240. The trade was a 7.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Roger Jeffs sold 20,252 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total value of $289,198.56. Following the completion of the transaction, the chief executive officer owned 1,038,560 shares in the company, valued at $14,830,636.80. This trade represents a 1.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,277 shares of company stock valued at $1,469,392 in the last ninety days. Company insiders own 30.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Hurley Capital LLC purchased a new position in Liquidia Technologies in the first quarter valued at about $32,000. GAMMA Investing LLC grew its stake in Liquidia Technologies by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock valued at $44,000 after purchasing an additional 1,173 shares in the last quarter. Quarry LP purchased a new position in Liquidia Technologies in the first quarter valued at about $79,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Liquidia Technologies by 24.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company's stock worth $77,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Liquidia Technologies by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after acquiring an additional 1,719 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.